摘要
類澱粉沉積心肌病變是一種罕見心臟疾病，隨著現代核子醫學造影檢查的進步，部分類澱粉沉積心肌病變已不需透過侵入性的心肌切片來診斷。而過去針對類澱粉沉積心肌病變之治療方法有限，大都採支持性療法或肝臟移植，但隨著醫學的進步，針對不同分類的類澱粉沉積心肌病變正積極研發適切的藥物治療，新興藥物tafamidis已經獲得核准使用於轉甲狀腺素蛋白類澱粉沉積心肌病變（transthyretin amyloid cardiomyopathy, ATTR-CM）的病患上。診斷與治療的進步促使類澱粉沉積心肌病變逐漸獲得關注，本篇著重在介紹類澱粉沉積心肌病變的治療。
參考文獻
Pitt B, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021;385:2252-63.
McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019;381:1995-2008.
Zampieri M, et al. SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series. Int Emergency Med 2022;17:1243-5.
Mints YY, et al. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Fail 2018;5:772-9.
King AM. Kates. Management of Cardiac Symptoms in Amyloidosis. Am J Med 2022;135:S9-S12.